论文部分内容阅读
降胆固醇治疗期间冠脉造影显示粥样硬化仅有轻度消退,不足以解释临床症状的明显改善。内皮调节舒张功能的恢复可能起重要作用。 本实验系洛伐他汀预防再狭窄试验的一部分,为前瞻性、多中心、随机双盲、安慰剂对照研究。患者年龄38～81岁,血胆固醇160～300mg％,无继发性高胆固醇血症、高甘油三酯血症、胰岛素依赖型糖尿病、心脏瓣膜病或肝肾疾病史、近期PTCA、CABG、不稳定型心绞痛和心肌梗塞均已除外。左主干病变、2支≥150％狭窄、待查冠脉近端内径<2mm、LVEF<(30％者亦均除外。符合条件23例患者分为2组:安慰剂组
Coronary angiography during hypoglycemic treatment showed only mild regression of atherosclerosis, not enough to explain the significant improvement in clinical symptoms. Endothelial modulation of diastolic function may play an important role in the recovery. Part of this trial of lovastatin in the prevention of restenosis was a prospective, multicenter, randomized, double-blind, placebo-controlled study. Patients aged 38-81 years old, blood cholesterol 160-300mg%, no secondary hypercholesterolemia, hypertriglyceridemia, insulin-dependent diabetes mellitus, valvular heart disease or history of liver and kidney disease, the recent PTCA, CABG, not Stable angina and myocardial infarction have been excluded. Left main disease, 2 ≥150% stenosis, the proximal diameter of the coronary artery to be investigated <2mm, LVEF <(30% were also excluded. Meet the conditions 23 patients were divided into two groups: placebo group